Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Abstract:
GeneSegues, Inc., a leader in drug delivery at the sub-50 nanometer scale, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent covering the company's proprietary drug delivery technology (EP Application No. 01920161.5). This patent stems from pioneering work by the company in delivering therapeutic molecules such as oligonucleotides and plasmid DNA to target cells using nanocapsules of less than 50 nanometers in diameter. Compositions of this size impart significant advantages including entering the target cell without triggering defense mechanisms that can degrade the capsule and drug.

GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Minneapolis, MN | Posted on March 6th, 2012

"We are gratified that the EPO has recognized the importance and patentability of our discoveries in nonviral technologies that can take advantage of efficient lipid raft pathways into the target cell," said Gretchen Unger, Ph.D., Chief Scientific Officer and founder of GeneSegues. "This patent covers a broad and significant technology platform which we are continuing to develop with collaborators across a range of applications including cancer, liver, and infectious diseases."

The new patent includes claims covering compositions of sub-50 nanometer capsules and methods of formulation. The composition claims cover sub-50 nanometer capsules that consist of a substitutable biopolymer ligand shell which can actively target the composition to any desired cell type, and can encapsulate large or small molecule drug cargo. The method claims cover the processes for formulating the nanocapsules with a novel design that is both versatile and scalable.

####

About GeneSegues, Inc.
GeneSegues is a biopharmaceutical company focused on applying its novel drug delivery technology to produce breakthrough nucleic acid-based therapeutics and vaccines for the treatment and prevention of serious diseases. The company’s sub-50 nanometer (‘s50’) capsule technology addresses the series of biological barriers that prevent nucleic acids from reaching the therapeutically-important cytoplasm and nucleus of the target cell.

For more information, please click here

Contacts:
Gretchen Unger, Ph.D.
Chief Scientific Officer
GeneSegues, Inc.
952.443.3798

Copyright © GeneSegues, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A step closer to understanding quantum mechanics: Swansea University’s physicists develop a new quantum simulation protocol October 22nd, 2017

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Tech’s Contribution Includes Liten’s Knowhow in Magnetic Materials and Simulation And Leti’s Expertise in Wide-bandgap Semiconductors October 20th, 2017

Nanomedicine

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice October 3rd, 2017

Announcements

A step closer to understanding quantum mechanics: Swansea University’s physicists develop a new quantum simulation protocol October 22nd, 2017

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Tech’s Contribution Includes Liten’s Knowhow in Magnetic Materials and Simulation And Leti’s Expertise in Wide-bandgap Semiconductors October 20th, 2017

Patents/IP/Tech Transfer/Licensing

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Nanoparticles limit damage in spinal cord injury: Injection after an injury reduces inflammation and scarring September 6th, 2017

More durable, less expensive fuel cells: University of Delaware researchers have developed a new technology that could speed up the commercialization of fuel cell vehicles September 5th, 2017

Argonne National Laboratory’s Continuous ALD Technology Licensed Exclusively to Forge Nano July 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project